<DOC>
	<DOCNO>NCT01360554</DOCNO>
	<brief_summary>This multinational , multicenter , randomize , double-blinded , Phase 3 study compare efficacy safety treatment PF-00299804 treatment erlotinib patient advance non-small cell lung cancer , previously treat least one prior regimen . Analyses primary objective ( Progression Free Survival ) do two co-primary population define protocol .</brief_summary>
	<brief_title>ARCHER 1009 : A Study Of Dacomitinib ( PF-00299804 ) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Evidence pathologically confirm , advance NSCLC ( know histology ) . Prior treatment least one two systemic therapy regimen ( least one must standard chemotherapy advanced NSCLC ) . Adequate tissue sample must submit prior randomization tumor biomarker analyse . Adequate renal , hematologic , liver function . ECOG PS 02 . Radiologically measurable disease . Small cell histology . Symptomatic brain mets know leptomeningeal mets . Prior therapy agent know propose active action EGFR tyrosine kinase HER family protein . Uncontrolled medical disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>comparative study PF-00299804 Erlotinib</keyword>
	<keyword>Double-Blind Phase 3 trial TKI</keyword>
</DOC>